A new daily pill called daraxonrasib has shown promising results in clinical trials by significantly extending survival times for those with advanced pancreatic cancer. By targeting a specific gene mutation that drives tumour growth, this treatment offers a potential breakthrough for a condition that has historically been very difficult to manage.